BioMarin Provides BMN 673 Program Update

BioMarin Provides BMN 673 Program Update

 RECIST Response Rate Increases to 50% in gBRCA Breast Cancer; Study Ongoing

                      Phase 3 Trial to Start in 3Q 2013

  National Breast Cancer Coalition Announces Intention to Assist With Trial
                                 Recruitment

SAN RAFAEL, Calif., July 25, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical
Inc. (Nasdaq:BMRN) today provided an update on its ongoing Phase 1/2 study for
its poly ADP-ribose polymerase (PARP) inhibitor BMN 673 for the treatment of
solid tumors. As of July 24, the RECIST response rate from the ongoing trial
is nine out of 18 breast cancer patients, or 50 percent, including one
confirmed complete response.This response rate includes three additional
confirmed responses since the last update at the ASCO Annual Meeting, and two
new patients are yet to be confirmed.Four patients are ongoing with stable
disease with potential for additional responses.The study is still ongoing,
and the company will provide additional updates later this year, including
data in ovarian cancer, Ewing's sarcoma and small cell lung cancer.

Since the ASCO Annual Meeting, the company has met with the FDA and MAA to
review its planned clinical program in deleterious gBRCA mutation metastatic
breast cancer. At those meetings, health authorities confirmed that a primary
endpoint of Progression Free Survival (PFS) could serve as the basis for a
potential approval.BioMarin now expects to initiate a Phase 3 trial for BMN
673 in deleterious gBRCA mutation metastatic breast cancer in late third
quarter of 2013, earlier than previously announced at the ASCO Annual Meeting
in early June.

National Breast Cancer Coalition (NBCC) has announced its intention to assist
BioMarin's development of the PARP inhibitor for the treatment of hereditary
breast cancer with BRCA mutations.NBCC intends to participate with BioMarin
on enrollment initiatives in the United States and around the world.In
addition, NBCC will be a resource on study design, implementation and
execution.

"NBCC is an organization committed to ending breast cancer in large part by
participating in and contributing to the scientific process.The application
of drug development science to well-defined problems is an important step in
our mission.Therefore, we are pleased to collaborate with BioMarin to develop
BMN 673 as a potential first and/or best in class PARP inhibitor for patients
with hereditary forms of cancer, namely BRCA mutations.This project offers
the hope of improving the length and/or quality of life for patients," said
Fran Visco, President of the National Breast Cancer Coalition.

"We look forward to conducting a world-class study, in collaboration with the
finest clinical investigators in the world to evaluate the safety and efficacy
of BMN 673 in the metastatic setting. Our advocates are poised to change the
world through our actions. Ultimately, we hope to prevent women from getting
breast cancer and prevent it fromspreading outside the breast," Visco added.

"BioMarin is an organization that wants to make big differences in the lives
of patients.The data emerging from the ongoing BMN 673 study is progressively
more encouraging.We are committed to the successful execution of the Phase 3
program in hopes of offering patients a safe and easily administered pill,
which is an effective treatment option," said Hank Fuchs, M.D., Chief Medical
Officer of BioMarin."We are honored to include a seat at the table for our
colleagues from NBCC.The purpose of our efforts is best served hearing their
voice from the beginning and taking action together."

About the National Breast Cancer Coalition (NBCC)

The National Breast Cancer Coalition (NBCC) is dedicated to knowing how to end
breast cancer by January 1, 2020 through the power of grassroots action and
advocacy. NBCCincreases funding for innovative breast cancer research;
monitors how those funds are spent; expands access to quality health care for
all; and ensures that trained advocates influence all decision making in
breast cancer. Join NBCC, learn more and take action visit
BreastCancerDeadline2020.org.

About Hereditary Breast Cancer with BRCA Mutation

BRCA1 and BRCA2 are human genes that belong to a class of genes known as tumor
suppressors. Mutation of these genes has been linked to hereditary breast and
ovarian cancer.A woman's risk of developing breast and/or ovarian cancer is
greatly increased if she inherits a deleterious (harmful) BRCA1 or BRCA2
mutation. Men with these mutations also have an increased risk of breast
cancer. Both men and women who have harmful BRCA1 or BRCA2 mutations may be at
increased risk of other cancers.

Source:National Cancer Institute at the National Institutes of Health
http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA

About BMN 673 Phase 1 Trial Data

BioMarin is conducting an ongoing Phase 1 study for its poly ADP-ribose
polymerase (PARP) inhibitor BMN 673 for the treatment of solid tumors. BMN 673
has exhibited substantial single-agent anti-tumor activity in deleterious
germline BRCA breast cancers in the trial. The preliminary data were presented
during a poster presentation at the 2013 American Society of Clinical Oncology
Annual Meeting on June 3, 2013.

The Phase 1 trial is an open-label study of once-daily, orally-administered
BMN 673 in approximately 70 patients ages 18 and older with advanced or
recurrent solid tumors.The primary objective of the study is to establish the
maximum tolerated dose (MTD) of daily oral BMN 673.The secondary objectives
are to assess the safety, tolerability, preliminary efficacy and
pharmacodynamic activity of BMN 673, and to determine the pharmacokinetic
profile.The study design was a standard 3 + 3 dose escalation followed by
expansion at MTD in cohorts with selected tumor types to further characterize
safety and anti-tumor activity.

BMN 673 was generally well-tolerated. The dose-limiting toxicity was Grade 4
thrombocytopenia. Myelosuppression, most of which was moderate in severity,
occurred in 10-20% of patients with chronic dosing.Fatigue, nausea and
alopecia were observed in 20-30% of patients.Signs of activity were seen at
doses as low as 100 µg/day, and the maximum tolerated dose was 1000 mg/day
(1.0 mg/day), which is the expected dose for further development.BMN 673 also
has good bioavailability and a long half-life which supports once-daily
dosing.

To access the poster presented at ASCO

http://www.bmrn.com/pipeline/clinical-trials/asco.php

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio comprises
four approved products and multiple clinical and pre-clinical product
candidates. Approved products include Naglazyme® (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis
I (MPS I), a product which BioMarin developed through a 50/50 joint venture
with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for
phenylketonuria (PKU), developed in partnership with Merck Serono, a division
of Merck KGaA of Darmstadt, Germany; and Firdapse® (amifampridine), which has
been approved by the European Commission for the treatment of Lambert Eaton
Myasthenic Syndrome (LEMS). Product candidates include Vimizim
(N-acetylgalactosamine 6-sulfatase), formally referred to as GALNS, which
successfully completed Phase III clinical development for the treatment of MPS
IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is
currently in Phase III clinical development for the treatment of PKU, BMN-701,
a novel fusion protein of insulin-like growth factor 2 and acid alpha
glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development
for the treatment of Pompe disease, BMN 673, a poly ADP-ribose polymerase
(PARP) inhibitor, which is currently in Phase I/II clinical development for
the treatment of genetically-defined cancers, and BMN-111, a modified
C-natriuretic peptide, which is currently in Phase I clinical development for
the treatment of achondroplasia. For additional information, please visit
www.BMRN.com. Information on BioMarin's website is not incorporated by
reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business
prospects of BioMarin Pharmaceutical Inc., including, without limitation,
statements about: the expectations of the development of BMN 673, including
the timing of the clinical trials of the candidate, and the possible safety
and efficacy of such candidate, and the participation of NBCC in the trial
execution. These forward-looking statements are predictions and involve risks
and uncertainties such that actual results may differ materially from these
statements. These risks and uncertainties include, among others: the content
and timing of decisions by the U.S. Food and Drug Administration, the European
Commission and other regulatory authorities, results and timing of current and
planned clinical and preclinical studies related to such product; our ability
to successfully manufacture the product; NBCC actual level of involvement with
the trials; and those factors detailed in BioMarin's filings with the
Securities and Exchange Commission, including, without limitation, the factors
contained under the caption "Risk Factors" in BioMarin's 2012 Annual Report on
Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q.
Stockholders are urged not to place undue reliance on forward-looking
statements, which speak only as of the date hereof. BioMarin is under no
obligation, and expressly disclaims any obligation to update or alter any
forward-looking statement, whether as a result of new information, future
events or otherwise.

Vimizim™ is our trademark, and BioMarin^®, Naglazyme^®, Kuvan^®, Firdapse^®
are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme^® is a registered trademark of BioMarin/Genzyme LLC.

CONTACT: Investors and Media:
         Debra Charlesworth
         BioMarin Pharmaceutical Inc.
         (415) 455-7451

BioMarin Pharmaceutical Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.